{"id": "article-41826_0", "title": "Cilostazol -- Continuing Education Activity", "content": "Cilostazol is a quinolone derivative primarily used to treat intermittent claudication due to peripheral vascular disease, the FDA-approved indication. Cilostazol is also indicated for secondary prevention in patients with a history of transient ischemic attacks or non-cardioembolic ischaemic stroke. Cilostazol improves walking distance by promoting vasodilation and antiplatelet activity with inhibition of phosphodiesterase III and subsequent increases in available cAMP. This activity reviews the indications, contraindications, and use of cilostazol and highlights the role of the interprofessional team in monitoring the adverse effects of the drug.", "contents": "Cilostazol -- Continuing Education Activity. Cilostazol is a quinolone derivative primarily used to treat intermittent claudication due to peripheral vascular disease, the FDA-approved indication. Cilostazol is also indicated for secondary prevention in patients with a history of transient ischemic attacks or non-cardioembolic ischaemic stroke. Cilostazol improves walking distance by promoting vasodilation and antiplatelet activity with inhibition of phosphodiesterase III and subsequent increases in available cAMP. This activity reviews the indications, contraindications, and use of cilostazol and highlights the role of the interprofessional team in monitoring the adverse effects of the drug."}
{"id": "article-41826_1", "title": "Cilostazol -- Continuing Education Activity", "content": "Objectives: Identify the mechanisms of action of cilostazol. Describe the adverse effects of cilostazol. Review and select appropriate monitoring of cilostazol. Summarize how the interprofessional team can collaborate to optimize therapeutic results with cilostazol. Access free multiple choice questions on this topic.", "contents": "Cilostazol -- Continuing Education Activity. Objectives: Identify the mechanisms of action of cilostazol. Describe the adverse effects of cilostazol. Review and select appropriate monitoring of cilostazol. Summarize how the interprofessional team can collaborate to optimize therapeutic results with cilostazol. Access free multiple choice questions on this topic."}
{"id": "article-41826_2", "title": "Cilostazol -- Indications", "content": "Cilostazol\u00a0is a\u00a0quinolone derivative\u00a0and is FDA approved for the treatment of intermittent claudication associated with early-stage peripheral\u00a0vascular disease. [1] Intermittent claudication is caused by the narrowing of arteries that supply the legs with oxygenated blood. Patients with intermittent claudication develop pain when walking due to a lack of oxygen-containing blood reaching the operating leg muscles. Cilostazol decreases the pain of intermittent claudication by dilating these arteries, which improves blood flow and oxygen to the legs.\u00a0Cilostazol\u00a0is an effective therapy for improving walking distances in patients with intermittent claudication, and the artery disease guidelines of the American College of Cardiology/American Heart Association reference a therapeutic trial of cilostazol. [2] [Level I]", "contents": "Cilostazol -- Indications. Cilostazol\u00a0is a\u00a0quinolone derivative\u00a0and is FDA approved for the treatment of intermittent claudication associated with early-stage peripheral\u00a0vascular disease. [1] Intermittent claudication is caused by the narrowing of arteries that supply the legs with oxygenated blood. Patients with intermittent claudication develop pain when walking due to a lack of oxygen-containing blood reaching the operating leg muscles. Cilostazol decreases the pain of intermittent claudication by dilating these arteries, which improves blood flow and oxygen to the legs.\u00a0Cilostazol\u00a0is an effective therapy for improving walking distances in patients with intermittent claudication, and the artery disease guidelines of the American College of Cardiology/American Heart Association reference a therapeutic trial of cilostazol. [2] [Level I]"}
{"id": "article-41826_3", "title": "Cilostazol -- Indications", "content": "Cilostazol has also been\u00a0used off-labeled for the long-term prevention of severe vascular events in patients with a history of transient ischemic attack or non-cardioembolic ischemic stroke. [3] Cilostazol is also\u00a0used off-labeled for percutaneous coronary intervention (PCI,\u00a0following elective stent placement). [4]", "contents": "Cilostazol -- Indications. Cilostazol has also been\u00a0used off-labeled for the long-term prevention of severe vascular events in patients with a history of transient ischemic attack or non-cardioembolic ischemic stroke. [3] Cilostazol is also\u00a0used off-labeled for percutaneous coronary intervention (PCI,\u00a0following elective stent placement). [4]"}
{"id": "article-41826_4", "title": "Cilostazol -- Mechanism of Action", "content": "Cilostazol is a phosphodiesterase III (PDE3) inhibitor. PDE3s are\u00a0enzymes that utilize a catalytic core to hydrolyze cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). [5] Phosphodiesterase III enzymes are primarily located within the cardiac sarcoplasmic reticulum and in the smooth muscle of arteries and veins, where they regulate cardiac and vascular smooth muscle contractility. Cilostazol exerts its action by inhibiting phosphodiesterase activity and suppressing cAMP degradation. The inhibition of PDE3 allows for a rise in\u00a0cAMP in platelets and blood vessels. Increased concentrations of cAMP subsequently lead to increase concentrations of the active form of protein kinase A (PKA), and increased PKA is directly related to the inhibition of platelet aggregation. [6] Elevated concentrations of intracellular PKA also elicit a vasodilatory effect on smooth muscle cells by preventing contraction through the inactivation of myosin light-chain kinase. [7]", "contents": "Cilostazol -- Mechanism of Action. Cilostazol is a phosphodiesterase III (PDE3) inhibitor. PDE3s are\u00a0enzymes that utilize a catalytic core to hydrolyze cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). [5] Phosphodiesterase III enzymes are primarily located within the cardiac sarcoplasmic reticulum and in the smooth muscle of arteries and veins, where they regulate cardiac and vascular smooth muscle contractility. Cilostazol exerts its action by inhibiting phosphodiesterase activity and suppressing cAMP degradation. The inhibition of PDE3 allows for a rise in\u00a0cAMP in platelets and blood vessels. Increased concentrations of cAMP subsequently lead to increase concentrations of the active form of protein kinase A (PKA), and increased PKA is directly related to the inhibition of platelet aggregation. [6] Elevated concentrations of intracellular PKA also elicit a vasodilatory effect on smooth muscle cells by preventing contraction through the inactivation of myosin light-chain kinase. [7]"}
{"id": "article-41826_5", "title": "Cilostazol -- Mechanism of Action", "content": "Myosin light-chain kinase\u00a0normally phosphorylates the light chain of myosin in the presence of\u00a0calcium and calmodulin, which\u00a0activates myosin to interact with actin. With the inactivation of myosin light-chain kinase by PKA, the myosin-actin interaction cannot occur, and\u00a0thus, there is\u00a0an inability to generate a smooth muscle contraction. [8]", "contents": "Cilostazol -- Mechanism of Action. Myosin light-chain kinase\u00a0normally phosphorylates the light chain of myosin in the presence of\u00a0calcium and calmodulin, which\u00a0activates myosin to interact with actin. With the inactivation of myosin light-chain kinase by PKA, the myosin-actin interaction cannot occur, and\u00a0thus, there is\u00a0an inability to generate a smooth muscle contraction. [8]"}
{"id": "article-41826_6", "title": "Cilostazol -- Mechanism of Action", "content": "Cilostazol has also recently been demonstrated to reduce plasma triglycerides and increase HDL cholesterol concentrations. [9] The precise mechanisms of cilostazol's ability to lower plasma triglycerides and increase HDL are\u00a0currently not understood; however, the lipoprotein effects of cilostazol are likely a result of the inhibition of cyclic nucleotide phosphodiesterase with a precipitant elevation of intracellular cAMP. As of now, several possible mechanisms have been proposed by which increased cAMP\u00a0could result in lowered plasma triglycerides. One possible\u00a0explanation is the reduction of hepatic triglyceride secretion (either directly or indirectly) by the increased effectiveness of\u00a0glucagon in inhibiting VLDL secretion. [10] Alternatively, increased cAMP intracellular concentrations have\u00a0demonstrated the ability to promote the release of lipoprotein lipase from rat adipocytes,\u00a0which could also result in reduced plasma triglycerides. [11]", "contents": "Cilostazol -- Mechanism of Action. Cilostazol has also recently been demonstrated to reduce plasma triglycerides and increase HDL cholesterol concentrations. [9] The precise mechanisms of cilostazol's ability to lower plasma triglycerides and increase HDL are\u00a0currently not understood; however, the lipoprotein effects of cilostazol are likely a result of the inhibition of cyclic nucleotide phosphodiesterase with a precipitant elevation of intracellular cAMP. As of now, several possible mechanisms have been proposed by which increased cAMP\u00a0could result in lowered plasma triglycerides. One possible\u00a0explanation is the reduction of hepatic triglyceride secretion (either directly or indirectly) by the increased effectiveness of\u00a0glucagon in inhibiting VLDL secretion. [10] Alternatively, increased cAMP intracellular concentrations have\u00a0demonstrated the ability to promote the release of lipoprotein lipase from rat adipocytes,\u00a0which could also result in reduced plasma triglycerides. [11]"}
{"id": "article-41826_7", "title": "Cilostazol -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Cilostazol is absorbed after oral administration. A high-fat meal increases absorption, with an approximately 90% increase in\u00a0peak serum concentration and a 25% increase in plasma concentration of\u00a0the drug\u00a0over time. [12] Distribution: Cilostazol is 95% to 98% protein-bound, predominantly to albumin. The free fraction of cilostazol\u00a0is 27% higher in subjects with renal impairment than in healthy volunteers.", "contents": "Cilostazol -- Mechanism of Action -- Pharmacokinetics. Absorption: Cilostazol is absorbed after oral administration. A high-fat meal increases absorption, with an approximately 90% increase in\u00a0peak serum concentration and a 25% increase in plasma concentration of\u00a0the drug\u00a0over time. [12] Distribution: Cilostazol is 95% to 98% protein-bound, predominantly to albumin. The free fraction of cilostazol\u00a0is 27% higher in subjects with renal impairment than in healthy volunteers."}
{"id": "article-41826_8", "title": "Cilostazol -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Cilostazol metabolism occurs extensively in\u00a0the liver by hepatic cytochrome P450 enzymes (mainly CYP3A4 and, to a lesser extent, CYP2C19). Two metabolites are primarily active, with one appearing to account for at least half of the pharmacologic activity (PDE3 inhibition) after the administration of the drug Excretion: Cilostazol is predominately eliminated by urinary excretion of metabolites (74%), with the remainder being excreted fecally (20%). [13]", "contents": "Cilostazol -- Mechanism of Action -- Pharmacokinetics. Metabolism: Cilostazol metabolism occurs extensively in\u00a0the liver by hepatic cytochrome P450 enzymes (mainly CYP3A4 and, to a lesser extent, CYP2C19). Two metabolites are primarily active, with one appearing to account for at least half of the pharmacologic activity (PDE3 inhibition) after the administration of the drug Excretion: Cilostazol is predominately eliminated by urinary excretion of metabolites (74%), with the remainder being excreted fecally (20%). [13]"}
{"id": "article-41826_9", "title": "Cilostazol -- Administration", "content": "Cilostazol is available in 50 mg and 100 mg tablets. It can be dosed and administered for the following conditions. Cilostazol should be administered orally with water 30 minutes before or 2 hours after meals (breakfast and dinner).\u00a0Do not\u00a0take cilostazol with grapefruit juice, which may impair drug metabolism. [14] Peak pharmacodynamic effects (increased heart rate, antiplatelet activity, decrease in diastolic blood pressure) usually occur within 6 hours. [15] Patients may experience symptomatic relief of intermittent claudication within\u00a0two to four weeks; however, it can take 12 weeks to\u00a0obtain\u00a0the optimal therapeutic effect. The dose of\u00a0cilostazol can be reduced or discontinued without a rebound phenomenon.", "contents": "Cilostazol -- Administration. Cilostazol is available in 50 mg and 100 mg tablets. It can be dosed and administered for the following conditions. Cilostazol should be administered orally with water 30 minutes before or 2 hours after meals (breakfast and dinner).\u00a0Do not\u00a0take cilostazol with grapefruit juice, which may impair drug metabolism. [14] Peak pharmacodynamic effects (increased heart rate, antiplatelet activity, decrease in diastolic blood pressure) usually occur within 6 hours. [15] Patients may experience symptomatic relief of intermittent claudication within\u00a0two to four weeks; however, it can take 12 weeks to\u00a0obtain\u00a0the optimal therapeutic effect. The dose of\u00a0cilostazol can be reduced or discontinued without a rebound phenomenon."}
{"id": "article-41826_10", "title": "Cilostazol -- Administration -- Intermittent Claudication", "content": "100 mg orally twice daily. 50 mg orally twice daily should be considered during the coadministration of CYP3A4 inhibitors such as diltiazem, erythromycin, ketoconazole, and itraconazole, and during coadministration of CYP2C19 inhibitors such as omeprazole.", "contents": "Cilostazol -- Administration -- Intermittent Claudication. 100 mg orally twice daily. 50 mg orally twice daily should be considered during the coadministration of CYP3A4 inhibitors such as diltiazem, erythromycin, ketoconazole, and itraconazole, and during coadministration of CYP2C19 inhibitors such as omeprazole."}
{"id": "article-41826_11", "title": "Cilostazol -- Administration -- Thrombotic Complications of Coronary Angioplasty", "content": "100 mg orally twice daily can be substituted for either aspirin or clopidogrel as part of a dual antiplatelet regimen in patients with coronary artery stents who have an allergy or intolerance to aspirin or clopidogrel.", "contents": "Cilostazol -- Administration -- Thrombotic Complications of Coronary Angioplasty. 100 mg orally twice daily can be substituted for either aspirin or clopidogrel as part of a dual antiplatelet regimen in patients with coronary artery stents who have an allergy or intolerance to aspirin or clopidogrel."}
{"id": "article-41826_12", "title": "Cilostazol -- Administration -- Secondary Prevention of Non-cardioembolic Stroke or TIA(off-label use)", "content": "100 mg orally twice daily (first-line drugs are aspirin and clopidogrel). [16]", "contents": "Cilostazol -- Administration -- Secondary Prevention of Non-cardioembolic Stroke or TIA(off-label use). 100 mg orally twice daily (first-line drugs are aspirin and clopidogrel). [16]"}
{"id": "article-41826_13", "title": "Cilostazol -- Administration -- Use in Special Population", "content": "Hepatic Impairment: The pharmacokinetic parameters of cilostazol and its metabolites are similar in healthy subjects compared to subjects with mild hepatic diseases. The use of cilostazol in patients with moderate/severe hepatic impairment is not analyzed.", "contents": "Cilostazol -- Administration -- Use in Special Population. Hepatic Impairment: The pharmacokinetic parameters of cilostazol and its metabolites are similar in healthy subjects compared to subjects with mild hepatic diseases. The use of cilostazol in patients with moderate/severe hepatic impairment is not analyzed."}
{"id": "article-41826_14", "title": "Cilostazol -- Administration -- Use in Special Population", "content": "Renal Impairment: The pharmacologic activity of cilostazol and its metabolites was similar in healthy subjects compared to subjects with mild to moderate renal impairment. In patients with severe renal impairment, metabolite levels are increased, altering the protein binding. However, the expected pharmacologic activity based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites appeared little changed.", "contents": "Cilostazol -- Administration -- Use in Special Population. Renal Impairment: The pharmacologic activity of cilostazol and its metabolites was similar in healthy subjects compared to subjects with mild to moderate renal impairment. In patients with severe renal impairment, metabolite levels are increased, altering the protein binding. However, the expected pharmacologic activity based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites appeared little changed."}
{"id": "article-41826_15", "title": "Cilostazol -- Administration -- Use in Special Population", "content": "Pregnancy Considerations: Teratogenic Effects:\u00a0Pregnancy Category C.\u00a0Cilostazol is teratogenic in rats at doses fivefold the human maximum recommended human dose on a body surface area basis. There are no adequate and well-controlled studies on pregnant women.", "contents": "Cilostazol -- Administration -- Use in Special Population. Pregnancy Considerations: Teratogenic Effects:\u00a0Pregnancy Category C.\u00a0Cilostazol is teratogenic in rats at doses fivefold the human maximum recommended human dose on a body surface area basis. There are no adequate and well-controlled studies on pregnant women."}
{"id": "article-41826_16", "title": "Cilostazol -- Administration -- Use in Special Population", "content": "Breastfeeding Considerations: Because there is no information on using cilostazol during breastfeeding, an alternate drug may be preferred, especially while nursing a preterm infant or newborn. If a nursing mother uses it, monitor the infant for bruising and bleeding. [17]", "contents": "Cilostazol -- Administration -- Use in Special Population. Breastfeeding Considerations: Because there is no information on using cilostazol during breastfeeding, an alternate drug may be preferred, especially while nursing a preterm infant or newborn. If a nursing mother uses it, monitor the infant for bruising and bleeding. [17]"}
{"id": "article-41826_17", "title": "Cilostazol -- Adverse Effects", "content": "Cilostazol is a generally well-tolerated oral medication. Common side effects of cilostazol therapy reportedly include headache (34%), diarrhea (19%), and palpitations (10%). [18]", "contents": "Cilostazol -- Adverse Effects. Cilostazol is a generally well-tolerated oral medication. Common side effects of cilostazol therapy reportedly include headache (34%), diarrhea (19%), and palpitations (10%). [18]"}
{"id": "article-41826_18", "title": "Cilostazol -- Adverse Effects", "content": "A\u00a0slight\u00a0elevation in heart rate\u00a0of 5 to 7 beats/min may also occur with the administration of cilostazol. These side effects are\u00a0mild to moderate in intensity, transient, or\u00a0alleviated\u00a0with symptomatic treatment and seldom demand treatment withdrawal. [13] Cilostazol may induce tachycardia, tachyarrhythmia, and hypotension. [19]", "contents": "Cilostazol -- Adverse Effects. A\u00a0slight\u00a0elevation in heart rate\u00a0of 5 to 7 beats/min may also occur with the administration of cilostazol. These side effects are\u00a0mild to moderate in intensity, transient, or\u00a0alleviated\u00a0with symptomatic treatment and seldom demand treatment withdrawal. [13] Cilostazol may induce tachycardia, tachyarrhythmia, and hypotension. [19]"}
{"id": "article-41826_19", "title": "Cilostazol -- Adverse Effects", "content": "Postmarketing research has shown cilostazol to induce thrombocytopenia or leukopenia, progressing to agranulocytosis when drug administration does not immediately discontinue. Agranulocytosis is reversible with immediate discontinuation of the drug. [20]", "contents": "Cilostazol -- Adverse Effects. Postmarketing research has shown cilostazol to induce thrombocytopenia or leukopenia, progressing to agranulocytosis when drug administration does not immediately discontinue. Agranulocytosis is reversible with immediate discontinuation of the drug. [20]"}
{"id": "article-41826_20", "title": "Cilostazol -- Contraindications", "content": "Box Warning : According to the manufacturer's labeling, Cilostazol administration is contraindicated in patients with heart failure of any grade. Cilostazol and many of its metabolites are inhibitors of phosphodiesterase III. Several drugs with the pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure. [21]", "contents": "Cilostazol -- Contraindications. Box Warning : According to the manufacturer's labeling, Cilostazol administration is contraindicated in patients with heart failure of any grade. Cilostazol and many of its metabolites are inhibitors of phosphodiesterase III. Several drugs with the pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure. [21]"}
{"id": "article-41826_21", "title": "Cilostazol -- Contraindications", "content": "Drugs with vasodilator-type properties generally decrease systemic blood pressure, resulting in a reduction in\u00a0lower limb\u00a0perfusion pressure. These agents may also cause a steal of blood from ischemic regions in which blood vessels\u00a0are already maximally dilated. Therefore, there have been questions regarding the\u00a0justification for treatment with vasodilators in claudication with absolute contraindication in patients with a history of heart failure. Phosphodiesterase inhibitors have demonstrated decreased survival compared with placebo in patients with class III to IV heart failure. Patients with a history of ischemic heart disease may incur an increased risk of angina pectoris or myocardial infarction exacerbation. [22] Thus, cilostazol is contraindicated in these populations.", "contents": "Cilostazol -- Contraindications. Drugs with vasodilator-type properties generally decrease systemic blood pressure, resulting in a reduction in\u00a0lower limb\u00a0perfusion pressure. These agents may also cause a steal of blood from ischemic regions in which blood vessels\u00a0are already maximally dilated. Therefore, there have been questions regarding the\u00a0justification for treatment with vasodilators in claudication with absolute contraindication in patients with a history of heart failure. Phosphodiesterase inhibitors have demonstrated decreased survival compared with placebo in patients with class III to IV heart failure. Patients with a history of ischemic heart disease may incur an increased risk of angina pectoris or myocardial infarction exacerbation. [22] Thus, cilostazol is contraindicated in these populations."}
{"id": "article-41826_22", "title": "Cilostazol -- Contraindications", "content": "Caution is also necessary when prescribing cilostazol to individuals with atrial or ventricular ectopy and those with atrial fibrillation or flutter.\u00a0Left ventricular outflow tract obstruction is another observation in patients with sigmoid-shaped interventricular septums undergoing cilostazol therapy. [23]", "contents": "Cilostazol -- Contraindications. Caution is also necessary when prescribing cilostazol to individuals with atrial or ventricular ectopy and those with atrial fibrillation or flutter.\u00a0Left ventricular outflow tract obstruction is another observation in patients with sigmoid-shaped interventricular septums undergoing cilostazol therapy. [23]"}
{"id": "article-41826_23", "title": "Cilostazol -- Monitoring", "content": "Patients with an increased risk for serious cardiac events\u00a0due to increased heart rate (patients with stable coronary disease) require close monitoring during treatment with cilostazol. Patients also need monitoring for bleeding episodes and easy bruising or other signs such as pyrexia and sore throat, suggesting the early development of blood dyscrasia. A\u00a0complete blood count is necessary if a\u00a0suspected infection or other clinical evidence suggests blood dyscrasia. If the patient shows any clinical or laboratory evidence of a hematologic abnormality, cilostazol therapy should be discontinued immediately.", "contents": "Cilostazol -- Monitoring. Patients with an increased risk for serious cardiac events\u00a0due to increased heart rate (patients with stable coronary disease) require close monitoring during treatment with cilostazol. Patients also need monitoring for bleeding episodes and easy bruising or other signs such as pyrexia and sore throat, suggesting the early development of blood dyscrasia. A\u00a0complete blood count is necessary if a\u00a0suspected infection or other clinical evidence suggests blood dyscrasia. If the patient shows any clinical or laboratory evidence of a hematologic abnormality, cilostazol therapy should be discontinued immediately."}
{"id": "article-41826_24", "title": "Cilostazol -- Monitoring", "content": "Caution is necessary when co-administering cilostazol with any other pharmacologic agent that can reduce blood pressure due to the possibility of an additive hypotensive effect with reflex tachycardia. Dual administration of\u00a0cilostazol with\u00a0other\u00a0antiplatelet\u00a0drugs also requires caution as there is a risk for spontaneous, prolonged, or excessive\u00a0bleeding. [24]", "contents": "Cilostazol -- Monitoring. Caution is necessary when co-administering cilostazol with any other pharmacologic agent that can reduce blood pressure due to the possibility of an additive hypotensive effect with reflex tachycardia. Dual administration of\u00a0cilostazol with\u00a0other\u00a0antiplatelet\u00a0drugs also requires caution as there is a risk for spontaneous, prolonged, or excessive\u00a0bleeding. [24]"}
{"id": "article-41826_25", "title": "Cilostazol -- Toxicity", "content": "The oral lethal dose of cilostazol is over 5 g/kg in rats and mice and more than 2 g/kg in dogs. There is a lack of data on acute overdosage with cilostazol in humans. The signs and symptoms of an acute cilostazol overdose can present as a severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmia. In an overdose, patients require careful observation and provide supportive treatment. Cilostazol is highly protein-bound and unlikely to be efficiently removed by hemodialysis or peritoneal dialysis. Emptying the stomach by gastric lavage may be appropriate if needed. [25]", "contents": "Cilostazol -- Toxicity. The oral lethal dose of cilostazol is over 5 g/kg in rats and mice and more than 2 g/kg in dogs. There is a lack of data on acute overdosage with cilostazol in humans. The signs and symptoms of an acute cilostazol overdose can present as a severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmia. In an overdose, patients require careful observation and provide supportive treatment. Cilostazol is highly protein-bound and unlikely to be efficiently removed by hemodialysis or peritoneal dialysis. Emptying the stomach by gastric lavage may be appropriate if needed. [25]"}
{"id": "article-41826_26", "title": "Cilostazol -- Enhancing Healthcare Team Outcomes", "content": "Healthcare professionals such as specialists, nurse practitioners, physician assistants, and physicians who plan to prescribe cilostazol should possess full knowledge regarding the indications and contraindications of the drug. Cilostazol's primary use is treating intermittent claudication, which typically correlates with early-stage peripheral\u00a0artery disease. [26]", "contents": "Cilostazol -- Enhancing Healthcare Team Outcomes. Healthcare professionals such as specialists, nurse practitioners, physician assistants, and physicians who plan to prescribe cilostazol should possess full knowledge regarding the indications and contraindications of the drug. Cilostazol's primary use is treating intermittent claudication, which typically correlates with early-stage peripheral\u00a0artery disease. [26]"}
{"id": "article-41826_27", "title": "Cilostazol -- Enhancing Healthcare Team Outcomes", "content": "Prescribing clinicians (MDs, DOs, NPs, PAs) should know that the drug is usually administered twice daily as a 100 mg oral dose\u00a0shortly before or after meals. Consider possible\u00a0adverse side\u00a0effects when using cilostazol in patients with supraventricular arrhythmias or a history of heart disease. Additionally, exercise caution when co-administering cilostazol with any other pharmacologic agent that\u00a0may reduce blood pressure due to an additive hypotensive effect\u00a0and subsequent reflex tachycardia; therefore, pharmacists should watch for these potential drug interactions and report back to the prescribing clinicians. Both pharmacists and nurses can counsel patients on optimal dosing and possible adverse reactions.", "contents": "Cilostazol -- Enhancing Healthcare Team Outcomes. Prescribing clinicians (MDs, DOs, NPs, PAs) should know that the drug is usually administered twice daily as a 100 mg oral dose\u00a0shortly before or after meals. Consider possible\u00a0adverse side\u00a0effects when using cilostazol in patients with supraventricular arrhythmias or a history of heart disease. Additionally, exercise caution when co-administering cilostazol with any other pharmacologic agent that\u00a0may reduce blood pressure due to an additive hypotensive effect\u00a0and subsequent reflex tachycardia; therefore, pharmacists should watch for these potential drug interactions and report back to the prescribing clinicians. Both pharmacists and nurses can counsel patients on optimal dosing and possible adverse reactions."}
{"id": "article-41826_28", "title": "Cilostazol -- Enhancing Healthcare Team Outcomes", "content": "Patients receiving\u00a0cilostazol should be closely monitored for tachyarrythmias, hypotension, and signs of blood dyscrasia, which will primarily be a function of nurses and report these findings to the prescribing clinician. The interprofessional health care team\u00a0should work collaboratively to ensure patients taking cilostazol obtain regular follow-ups. The specialty medical professionals should weigh in as needed in the care of these patients for optimal healthcare outcomes. [Level 5]", "contents": "Cilostazol -- Enhancing Healthcare Team Outcomes. Patients receiving\u00a0cilostazol should be closely monitored for tachyarrythmias, hypotension, and signs of blood dyscrasia, which will primarily be a function of nurses and report these findings to the prescribing clinician. The interprofessional health care team\u00a0should work collaboratively to ensure patients taking cilostazol obtain regular follow-ups. The specialty medical professionals should weigh in as needed in the care of these patients for optimal healthcare outcomes. [Level 5]"}
{"id": "article-41826_29", "title": "Cilostazol -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Cilostazol -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}